Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Delcath Systems Inc

DCTH ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: BUY

Last Close

$15.91

▲ +0.70%

Market Cap $552.06M · Vol 135.82K

Key Metrics

P/E Ratio

2,603.93

FWD: N/A

Market Cap

$552.06M

Small Cap

Div Yield

N/A

EPS Growth

-321.43%

YoY

RSI (14)

24.27

Momentum

Beta

0.62

vs Market

52W High

$17.41

8.62% below

52W Low

$8.12

95.94% above

Volume

135.82K

Avg 201.65K

P/B

3.15

Price-to-book

ROE

N/A

Return on equity

Free Float

91.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Delcath Systems Inc (DCTH) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DCTH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.46%

-7.61%

+35.23%

+64.36%

YTD

+57.52%

+42.95%

+230.77%

+53.72%

Financials & Valuation

TTM · Annual

Total Revenue	$85.23M
Net Income	$2.70M
Revenue Growth (YoY)	+20.60%
Gross Margin	86.16%
Operating Margin	0.77%
Net Profit Margin	3.17%
ROE	N/A
ROA · ROIC	3.51% · 3.00%

P/E Ratio	2,603.93
Forward P/E (FY1)	N/A
PEG Ratio	1.39
P/S	4.73
P/B	3.15
P/FCF	19.23
EPS Growth	-321.43%
Outstanding Shares	34.70M

Technical Indicators

50-Day SMA	$14.70
200-Day SMA	$11.41
RSI (14)	24.27
Beta	0.62
52-Week High	$17.41
52-Week Low	$8.12

Volume Today	135.82K
Avg Daily Volume (30D)	201.65K
Relative Volume	0.67x
Volatility (10D)	15.51
Volatility (30D)	71.89
Free Float	91.80%

Analyst Consensus

BUY

Current Price $15.91

Mean Target $24.50

52W Low$8.12 52W High$17.41

Current

Target

$8.12 $17.41

Current Analyst target

+53.99% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S81551

ISINUS24661P8077

CountryUSA

Sub-IndustryMedical Prosthetics

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

STMN.S Straumann Holding AG +0.56% SOON.S Sonova Holding AG -1.39% COH.AX Cochlear Limited -2.50% OBCK.DE Ottobock SE & Co KgaA +0.36% 6699.HK Angelalign Technology Inc. -5.51%

Company Profile

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).